GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.

"all data were analyzed using graphpad prism 9 software (graphpad software san diego ca) snrnaseq data are available at the national center for biotechnology information gene expression omnibus (geo) under accession number gse167981."

"Duality of Interest. This work was supported by an investigator-initiated sponsored agreement from Eli Lilly & Co. (M.R.H., B.C.D.J.). M.R.H. receives research funding from Boehringer Ingelheim that was not used in support of these studies. M.R.H. and B.C.D.J. are chief executive officer and chief scientific officer of Cantius Therapeutics, LLC, that pursues biological work unrelated to the current study. R.C., J.A.-F., M.D., M.A., and R.J.S. are employees of Eli Lilly & Co. No other potential conflicts of interest relevant to this article were reported."

"Funding. This work was supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grants DK021397 (M.R.H., H.J.G.) and DK112812 (B.C.D.J.), and by the Swiss National Science Foundation (Grant SNF P400PB_186728 to T.B.). B.C.R. is supported, in part, by a 2017 National Association for Research on Schizophrenia and Depression Young Investigator Grant (No. 26634) from the Brain and Behavior Research Foundation as the Patrick A. Coffer Investigator, funding for which was generously provided by Ronald and Kathy Chandonais."